UNSPSC 51372307: Loperamide oxide

This classification denotes an opioid and antidiarrheal agent with the molecular formula C29H33ClN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6X9OC3H4II, chemically known as 4-(4-chlorophenyl)-n,n-dimethyl-alpha,alpha-diphenyl-4-hydroxy-1-piperidinebutanamide but generally known as loperamide, which bears US NIH Compound Identifier 3955. European Medicines Agency schedules Loperamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08572MIG.

UNSPSC 51372307 Loperamide oxide is a Commodity code that in practice covers pharmaceutical procurement by state and local health authorities—but the recent solicitations under this code show activity centered on naloxone, safe drug deactivation systems, and broader generic pharmaceuticals and over-the-counter products rather than loperamide specifically. State and local issuing bodies soliciting under this code include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances. Seminole County, Florida and the Texas Health and Human Services Commission are recent buyers. The scope of work encompasses emergency-response pharmaceuticals (naloxone for opioid overdose), drug disposal and deactivation systems, generic multi-source pharmaceuticals with specific National Drug Codes for distribution across state and local facilities, and over-the-counter products. Vendors must comply with FDA requirements, current Good Manufacturing Practices (cGMP), the Drug Supply Chain Security Act (DSCSA), maintain relationships with authorized pharmaceutical wholesalers, and meet insurance and workplace-certification requirements including E-Verify compliance and drug-free workplace certification.

Recent activity spans Florida and Minnesota, with broader multistate reach through cooperative purchasing vehicles. Seminole County posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building; response deadline was July 26, 2023, on a two-year contract with one-year renewal option. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products distributed to state and local facilities including Oregon; proposals were due March 26, 2026, with contract effectiveness July 1, 2026. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels—a preliminary market-intelligence vehicle preceding formal solicitation.